Attention changes in epilepsy patients following 3-month topiramate or valproate treatment revealed by event-related potential.
The present study was designed to reveal changes of cognitive processes in epilepsy (EP) patients with Topiramate (TPM) or Valproate (VPA) treatment using Wechsler Adult Intelligence Scale (WAIS-CR) and event-related potential (ERP). Thirty untreated epilepsy patients were randomly divided into two groups receiving TPM or VPA, respectively. Fifteen healthy volunteers were included as controls. All the patients were examined by WAIS-CR and ERP before and 3 months after drug treatment. Controls were examined by ERP at the time recruited into the study and 3 months later. Unfamiliar grey-scale photographs of faces (front view) were used as stimuli. ERP were recorded at the same time. Mean Intelligence Quotient (IQ) in TPM group decreased after the 3-month treatment (90.40 vs. 81.00, P<0.05). One component of ERP-P300 was smaller in epilepsy patients than controls (P<0.05), but remained unchanged after TPM or VPA treatment (P>0.05). A delayed and smaller N270 was detected in patients compared to controls (P<0.05). After 3 months TPM treatment, it decreased further compared to before treatment (P<0.05). N170 was lower in patient groups, and it became lower after TPM treatment than before. Our results demonstrate that in all epilepsy patients with mild cognitive impairment ERP changes were found. TPM affected the cognitive functions in epilepsy patients reflected by the decreased full-scale intelligence quotient (FIQ). The imperative effects of TPM on visual perception function reflected by N170 were more obvious than that of VPA. Attention reflected by N270 was impaired after TPM treatment.
Sun
Wei
W
Department of Neurology, Capital Medical University Xuanwu Hospital, Beijing, 100053, People's Republic of China.
Wang
Yuping
Y
Wang
Weiwei
W
Wu
Xun
X
D000293:Adolescent; D000328:Adult; D001288:Attention / Q000187:drug effects*; D016022:Case-Control Studies; D004569:Electroencephalography; D004827:Epilepsy / Q000188:drug therapy / Q000503:physiopathology*; D005071:Evoked Potentials / Q000187:drug effects*; D005260:Female; D005500:Follow-Up Studies; D005632:Fructose / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010364:Pattern Recognition, Visual / Q000187:drug effects; D010775:Photic Stimulation / Q000379:methods; D000077236:Topiramate; D014635:Valproic Acid / Q000494:pharmacology* / Q000627:therapeutic use
D000077236:Topiramate; D005632:Fructose; D014635:Valproic Acid